UNIVERSITY OF SOUTHERN CALIFORNIA
NEW YORK, New York
Total Received
$669.7M
Total Awards
266
State
New York
Last Updated
Apr 1, 2026
Yearly Funding Trend
$559.8M24
$86.4M25
$23.5M26
Top 50 Awards to UNIVERSITY OF SOUTHERN CALIFORNIA
Largest individual federal awards on record for this recipient, ranked by obligated amount. Data through April 1, 2026.
| Award | Awarding Agency | Program | Place | FY | Obligation |
|---|---|---|---|---|---|
ASST_NON_P30CA033572_075 CANCER CENTER SUPPORT GRANT - THE CITY OF HOPE COMPREHENSIVE CANCER CENTER (COHCCC) RECEIVED NCI-DESIGNATION IN 1981 AND COMPREHENSIVE STATUS IN 1998. LED BY JOHN D. CARPTEN, PHD,… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | CA-90 | 2024 | $63,457,010 |
ASST_NON_P50CA107399_075 CITY OF HOPE LYMPHOMA SPORE - THE OVERALL GOAL OF THE CITY OF HOPE LYMPHOMA SPORE IS TO DEVELOP NOVEL THERAPEUTICS AND PROGNOSTICS REPRESENTING THE FOREFRONT OF KNOWLEDGE GAINED F… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | CA-90 | 2024 | $26,455,751 |
ASST_NON_U01CA199277_075 INNOVATIVE INFRASTRUCTURE TO ENHANCE AND SUSTAIN THE CALIFORNIA TEACHERS STUDY COHORT - PROJECT SUMMARY / ABSTRACT THE CALIFORNIA TEACHERS STUDY (CTS) HAS COLLECTED HIGH-QUALITY A… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | CA-90 | 2024 | $20,658,348 |
ASST_NON_UM1CA186717_075 PHASE 1 AND 2 MOLECULAR AND CLINICAL PHARMACODYNAMIC TRIALS ETCTN - PROJECT SUMMARY AS THE CALIFORNIA CANCER CONSORTIUM (CCC), FOUR NATIONAL CANCER INSTITUTE (NCI)-DESIGNATED CANC… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | DUARTE, CA-31 | 2024 | $17,918,626 |
ASST_NON_U24DK098085_075 INTEGRATED ISLET DISTRIBUTION PROGRAM (U24) - 2021 - PROJECT SUMMARY / ABSTRACT HUMAN PANCREATIC ISLETS ARE AN ESSENTIAL RESEARCH RESOURCE FOR RESEARCH ON THE PREVENTION, TREATMEN… | Department of Health and Human Services National Institutes of Health | 93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | DUARTE, CA-31 | 2024 | $14,918,013 |
ASST_NON_U24DK104162_075 RENEWAL OF THE HUMAN ISLET RESEARCH ENHANCEMENT CENTER (HIREC) FOR THE TYPE-1-DIABETES-FOCUSED HUMAN ISLET RESEARCH NETWORK (HIRN). - ABSTRACT THE SCALE AND SCOPE OF SCIENTIFIC CO… | Department of Health and Human Services National Institutes of Health | 93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | DUARTE, CA-31 | 2024 | $11,623,547 |
ASST_NON_K12CA001727_075 CITY OF HOPE CLINICAL ONCOLOGY CAREER RESEARCH DEVELOPMENT PROGRAM - ABSTRACT THE PAUL CALABRESI CAREER DEVELOPMENT AWARD FOR CLINICAL ONCOLOGY (K12 PROGRAM) AT THE CITY OF HOPE C… | Department of Health and Human Services National Institutes of Health | 93.398 CANCER RESEARCH MANPOWER | CA-90 | 2024 | $11,577,855 |
ASST_NON_U54CA209978_075 COMBATING SUBCLONAL EVOLUTION OF RESISTANT CANCER PHENOTYPES - OVERALL ABSTRACT OUR CANCER SYSTEMS BIOLOGY CENTER OF HOPE (HETEROGENEITY OF PHENOTYPIC EVOLUTION) WILL DEVELOP A SU… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | DUARTE, CA-31 | 2024 | $10,538,741 |
ASST_NON_R01CA242218_075 PRECISION APPROACHES TO REFINING TP53-ASSOCIATED CANCER RISK - PATHOGENIC TP53 GENE VARIANTS UNDERLIE 70% OF LI-FRAUMENI SYNDROME (LFS), A HEREDITARY CANCER SYNDROME CLASSICALLY A… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | CA-90 | 2025 | $8,533,340 |
ASST_NON_U01CA214254_075 EXOSOME-BASED MICRORNA BIOMARKERS FOR NON-INVASIVE AND EARLY DETECTION OF PANCREATIC CANCER - PANCREATIC CANCER IS A HIGHLY AGGRESSIVE MALIGNANCY THAT IS ESTIMATED TO BECOME THE S… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | DUARTE, CA-31 | 2024 | $7,986,946 |
ASST_NON_R35CA210087_075 HUMAN NATURAL KILLER CELLS: ADVANCING BIOLOGY AND CLINICAL APPLICATIONS - PROJECT SUMMARY THE CURRENT R35 COMPETITIVE RENEWAL IS REVISED FROM 2023 (SCORE 15). THE PANEL AND REVIEW… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | CA-90 | 2025 | $7,377,660 |
ASST_NON_R01HL106089_075 TRANSCRIPTIONAL REGULATION BY ANGIOTENSIN II IN VASCULAR SMOOTH MUSCLE CELLS - SUMMARY: VASCULAR SMOOTH MUSCLE CELLS (VSMCS) IN THE BLOOD VESSEL WALL PLAY PIVOTAL ROLES IN CARDIOV… | Department of Health and Human Services National Institutes of Health | 93.837 CARDIOVASCULAR DISEASES RESEARCH | CA-90 | 2024 | $6,572,026 |
ASST_NON_R01AI109644_075 CBFB IN RORGT-REGULATED T CELL FUNCTION - RETINOID-RELATED ORPHAN RECEPTOR GAMMA T (RORYT) IS A TRANSCRIPTION FACTOR THAT REGULATES THE DIFFERENTIATION OF TH17 CELLS IN THE PERIPH… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | CA-90 | 2024 | $6,130,598 |
ASST_NON_R01DK081705_075 TRANSFORMING GROWTH FACTOR BETA1, MICRORNAS, LNCRNA AND DIABETIC NEPHROPATHY - PROJECT SUMMARY DIABETIC KIDNEY DISEASE (DKD) IS A MAJOR DEBILITATING COMPLICATION OF DIABETES AND A… | Department of Health and Human Services National Institutes of Health | 93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | CA-90 | 2026 | $6,128,494 |
ASST_NON_R01DK065073_075 INFLAMMATORY GENE REGULATION IN DIABETIC CONDITIONS - PROJECT SUMMARY DIABETES, OBESITY AND INSULIN RESISTANCE (IR) ARE ASSOCIATED WITH CHRONIC INFLAMMATION IMPLICATED IN THE DEV… | Department of Health and Human Services National Institutes of Health | 93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | DUARTE, CA-31 | 2024 | $5,889,112 |
ASST_NON_R01CA073764_075 FEN1-MEDIATED OKAZAKI FRAGMENT MATURATION AND ITS DEFICIENCY IN CANCER - PROJECT SUMMARY THE LONG-TERM GOAL OF THIS PROJECT IS TO DEFINE MECHANISMS THAT REGULATE OKAZAKI FRAGMENT… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | CA-90 | 2024 | $5,640,854 |
ASST_NON_R01CA130899_075 IONIZING RADIATION-INDUCED DNA DAMAGE REPAIR - PARP INHIBITORS HAVE BEEN USED IN THE CLINICAL TREATMENT FOR TUMORS WITH BRCA1 OR BRCA2 MUTATIONS. THE MAJOR FUNCTION OF PARP INHIBI… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | CA-90 | 2026 | $5,453,163 |
ASST_NON_R01CA085344_075 DYNAMIC FUNCTIONS OF DNA2 COUNTERACT DNA REPLICATION STRESSES AND TUMORIGENESIS - SUMMARY CANCER CELLS ARISE AND PROGRESS DUE TO ACCUMULATION OF GENETIC AND EPIGENETIC ALTERATIONS… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | DUARTE, CA-31 | 2024 | $5,448,416 |
ASST_NON_HT94252510486_097 DIGITAL HEALTH INTERVENTION FOR SELF-MANAGEMENT AND TELEMONITORING IN CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY | Department of Defense Defense Health Agency | 12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT | DUARTE, CA-31 | 2025 | $5,339,958 |
ASST_NON_U01NS122101_075 A HUMAN IPSC-BASED CELL THERAPY FOR CANAVAN DISEASE - PROJECT SUMMARY CANAVAN DISEASE (CD) IS A RARE, AUTOSOMAL RECESSIVE NEURODEVELOPMENTAL DISORDER THAT AFFECTS CHILDREN FROM IN… | Department of Health and Human Services National Institutes of Health | 93.853 EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS | CA-90 | 2024 | $5,276,950 |
ASST_NON_R01DK067912_075 REGULATING SNARE MECHANISMS TO REMEDIATE GLUCOSE HOMEOSTASIS - PROJECT SUMMARY - TYPE 2 DIABETES (T2D) PLAGUES NEARLY 10% OF THE US POPULATION (~30 MILLION PEOPLE); A SHOCKING 84… | Department of Health and Human Services National Institutes of Health | 93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | CA-90 | 2026 | $5,234,458 |
ASST_NON_OT3HL152932_075 CURESC MANUFACTURING RESOURCE PLATFORM - AN OTHER TRANSACTION AGREEMENT AWARD WOULD ESTABLISH CITY OF HOPE AND ITS PRINCIPLE INVESTIGATOR, DR. JOSEPH GOLD, IN A LEADERSHIP ROLE TO… | Department of Health and Human Services National Institutes of Health | 93.837 CARDIOVASCULAR DISEASES RESEARCH | DUARTE, CA-31 | 2024 | $5,179,238 |
ASST_NON_P01HL170046_075 MUCUS-DEGRADING INTESTINAL BACTERIA AND TOXICITIES OF HEMATOPOIETIC CELL TRANSPLANTATION - OVERALL PROGRAM SUMMARY: MUCUS-DEGRADING INTESTINAL BACTERIA AND TOXICITIES OF HEMATOPOI… | Department of Health and Human Services National Institutes of Health | 93.837 CARDIOVASCULAR DISEASES RESEARCH | DUARTE, CA-31 | 2024 | $5,032,505 |
ASST_NON_R01CA154491_075 CONFORMAL TOTAL BODY AND MARROW IRRADIATION FOR LEUKEMIA - RELAPSE IS THE MAJOR CAUSE OF DEATH IN PATIENTS WITH POOR-RISK LEUKEMIA. INCREASING THE DOSE OF CONVENTIONAL TOTAL BODY… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | DUARTE, CA-31 | 2024 | $4,974,166 |
ASST_NON_R01CA205247_075 TARGETING MICRORNAS TO ERADICATE LEUKEMIA STEM CELLS - PROJECT SUMMARY LEUKEMIA STEM CELLS (LSCS) ARE AT THE APEX OF THE ACUTE MYELOID LEUKEMIA (AML) CELLULAR HIERARCHY. THE QUIES… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | CA-90 | 2024 | $4,808,601 |
ASST_NON_R01CA264911_075 UNMASKING THE ROLES OF VIRAL GLYCOPROTEINS IN ORAL TRANSMISSION OF KSHV - PROJECT SUMMARY MORE THAN 44,000 NEW CASES OF KAPOSI SARCOMA (KS) ARE REPORTED GLOBALLY EACH YEAR, 84% OF… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | CA-90 | 2024 | $4,786,354 |
ASST_NON_U19CA264512_075 DEVELOPMENT OF SMALL MOLECULE INHIBITORS AND BIOLOGIC AGENTS FOR TREATMENT OF GLIOBLASTOMA USING INTRACEREBRAL MICRODIALYSIS AND SIGNATURES OF VULNERABILITY - PROJECT SUMMARY - OV… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | DUARTE, CA-31 | 2024 | $4,645,634 |
ASST_NON_R33AG059206_075 GERIATRIC ONCOLOGY RESEARCH INFRASTRUCTURE TO IMPROVE CLINICAL CARE - THE OVERALL GOAL OF THIS FIVE YEAR R33 GRANT PROPOSAL, “GERIATRIC ONCOLOGY RESEARCH INFRASTRUCTURE TO IMPROVE… | Department of Health and Human Services National Institutes of Health | 93.866 AGING RESEARCH | DUARTE, CA-31 | 2024 | $4,459,258 |
ASST_NON_R01CA241845_075 VALIDATION OF EPIGENOMIC BIOMARKERS FOR THYROID CANCER DIAGNOSTICS - PROJECT SUMMARY/ABSTRACT EACH YEAR, UP TO 50,000 PATIENTS IN THE UNITED STATES RECEIVE UNNECESSARY THYROIDECTO… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | DUARTE, CA-31 | 2024 | $4,383,651 |
ASST_NON_R01HL137723_075 ROLE OF THE UNFOLDED PROTEIN RESPONSE IN PATHOLOGICAL CARDIAC REMODELING - PROJECT SUMMARY HEART FAILURE (HF) IS A LEADING CAUSE OF MORBIDITY AND MORTALITY WORLDWIDE. HYPERTENSIO… | Department of Health and Human Services National Institutes of Health | 93.837 CARDIOVASCULAR DISEASES RESEARCH | CA-90 | 2024 | $4,305,972 |
ASST_NON_R01AI151013_075 KSHV SUBUNIT VACCINE CANDIDATES TO ELICIT POTENT HUMORAL IMMUNE REPONSES AGAINST KSHV INFECTION - PROJECT SUMMARY KAPOSI SARCOMA-ASSOCIATED HERPESVIRUS (KSHV) HAS BEEN CLASSIFIED… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | DUARTE, CA-31 | 2024 | $4,284,115 |
ASST_NON_R01CA249460_075 TECHNOLOGY-ENABLED ACTIVATION OF SKIN CANCER SCREENING FOR HEMATOPOIETIC CELL TRANSPLANTATION SURVIVORS AND THEIR PRIMARY CARE PROVIDERS - SUMMARY/ABSTRACT HEMATOPOIETIC CELL TRAN… | Department of Health and Human Services National Institutes of Health | 93.353 21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT | DUARTE, CA-31 | 2024 | $4,101,503 |
ASST_NON_R01CA249501_075 SELF-MANAGEMENT TO OPTIMIZE SURVIVORSHIP CARE AND OUTCOMES IN LUNG AND COLORECTAL CANCER - PROJECT SUMMARY THE OVERARCHING GOAL OF THIS FIVE-YEAR GRANT PROPOSAL, SUBMITTED ON BEHA… | Department of Health and Human Services National Institutes of Health | 93.353 21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT | CA-90 | 2024 | $4,096,510 |
ASST_NON_U54CA285116_075 1/2 DRUG DEVELOPMENT AND CAPACITY BUILDING: A UCR/COH-CCC PARTNERSHIP - THE UNITED STATES HAS LED THE WORLD IN DRUG DISCOVERY FOR OVER 50 YEARS; HOWEVER, THE MAJORITY OF SCIENTIFI… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | DUARTE, CA-31 | 2024 | $4,072,339 |
ASST_NON_R25CA171998_075 CANCER GENETICS PROFESSIONAL EDUCATION IN A GLOBAL COMMUNITY OF PRACTICE - THE RAPID AND ONGOING INFUSION OF GENOMIC INFORMATION INTO CLINICAL PRACTICE CONTINUES TO FUEL THE NEED… | Department of Health and Human Services National Institutes of Health | 93.398 CANCER RESEARCH MANPOWER | CA-90 | 2024 | $3,935,914 |
ASST_NON_R01CA217841_075 A MULTIMEDIA SELF-MANAGEMENT INTERVENTION TO PREPARE FAMILY CAREGIVERS AND PATIENTS FOR LUNG CANCER SURGERY - PROJECT SUMMARY - THE OVERALL PURPOSE OF THIS PROPOSAL IS TO TEST THE… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | CA-90 | 2025 | $3,862,229 |
ASST_NON_R01GM117923_075 STRUCTURAL DYNAMICS UNDERLYING GPCR-G PROTEIN SELECTIVITY - SUMMARY: TITLE: STRUCTURAL DYNAMICS UNDERLYING GPCR-G PROTEIN SELECTIVITY UPON BINDING TO AGONISTS WITH DIFFERENT EFFIC… | Department of Health and Human Services National Institutes of Health | 93.859 BIOMEDICAL RESEARCH AND RESEARCH TRAINING | DUARTE, CA-31 | 2024 | $3,762,836 |
ASST_NON_R01CA139158_075 MIRNAS IN HEPATOCELLULAR CARCINOMA DEVELOPMENT AND TREATMENT - HEPATOCELLULAR CARCINOMA (HCC) IS THE MOST COMMON MALIGNANT TUMOR OF THE LIVER AND THE THIRD LEADING CAUSE OF DEATH… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | DUARTE, CA-31 | 2024 | $3,733,297 |
ASST_NON_R01CA254271_075 CLINICAL EVALUATION OF CHLOROTOXIN-REDIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR TREATMENT OF GLIOBLASTOMA - PROJECT SUMMARY DESPITE INCREASINGLY AGGRESSIVE STANDARD OF C… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | DUARTE, CA-31 | 2024 | $3,697,677 |
ASST_NON_U01CA264620_075 MECHANISM OF ESTROGEN INDEPENDENT PROLIFERATION IN ER+ BREAST CANCER CELLS - ABSTRACT COMBINING CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS WITH ENDOCRINE THERAPY IMPROVES OUTCOMES F… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | DUARTE, CA-31 | 2024 | $3,641,042 |
ASST_NON_U01CA250046_075 INFORMATION FLOW AND STATE TRANSITIONS AT THE SYSTEM AND MULTI-DIMENSIONAL SCALES IN LEUKEMIA PROGRESSION - PROJECT SUMMARY CANCER BEGINS AS A DISEASE OF THE GENOME, WITH DNA MUTA… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | CA-90 | 2024 | $3,616,836 |
ASST_NON_R01CA202712_075 RISK FACTORS FOR MOLECULAR SUBTYPES OF NHL A PROSPECTIVE EVALUATION - ABSTRACT IN THIS APPLICATION, WE AIM TO DIRECTLY ADDRESS KEY GAPS IN OUR KNOWLEDGE OF NHL ETIOLOGY AND PROMOT… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | DUARTE, CA-31 | 2024 | $3,603,721 |
ASST_NON_R01HL150069_075 CARDIOVASCULAR RESERVE CAPACITY IN SURVIVORS OF HEMATOPOIETIC CELL TRANSPLANTATION - ABSTRACT THERE ARE CURRENTLY 200,000 HEMATOPOIETIC CELL TRANSPLANTATION (HCT) SURVIVORS IN THE… | Department of Health and Human Services National Institutes of Health | 93.837 CARDIOVASCULAR DISEASES RESEARCH | DUARTE, CA-31 | 2024 | $3,529,164 |
ASST_NON_R01CA233664_075 DNA REPAIR GENE MUTATIONS AND PROSTATE CANCER - PROSTATE CANCER (PCA) IS ONE OF THE MOST HERITABLE HUMAN CANCERS, WITH INHERITED RISK ESTIMATES OF UP TO 60%; HOWEVER, THE UNDERLYI… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | CA-90 | 2024 | $3,444,954 |
ASST_NON_R01CA233922_075 TARGETING P38 GAMMA SIGNALING TO ADVANCE CUTANEOUS T CELL LYMPHOMA THERAPY - CUTANEOUS T CELL LYMPHOMA (CTCL) IS A DISFIGURING, INCURABLE CANCER. FOR PATIENTS WITH ADVANCED DISEAS… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | CA-90 | 2025 | $3,431,016 |
ASST_NON_R01CA261793_075 LEVERAGING DIGITAL HEALTH SOLUTIONS TO REDUCE LEARNING AND FUNCTIONAL DISPARITIES IN CHILDREN WITH CANCER - ADMINISTRATIVE SUPPLEMENT - PROJECT SUMMARY/ABSTRACT ADMINISTRATIVE SUP… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | DUARTE, CA-31 | 2024 | $3,407,172 |
ASST_NON_R01CA227230_075 (PQ11) IMMUNE MODULATORY EFFECTS OF WHITE BUTTON MUSHROOM IN PROSTATE CANCER - A TRANSLATIONAL RESEARCH - PROJECT SUMMARY PROSTATE CANCER IS THE MOST COMMON CANCER AND THE SECOND… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | CA-90 | 2025 | $3,330,880 |
ASST_NON_R50CA211397_075 FUNCTIONAL ANALYSIS OF STRUCTURE SPECIFIC NUCLEASES IN GENOME STABILITY AND CANCERS - ABSTRACT THE PROPOSED R50 AWARD WILL SUPPORT MY CRITICAL CONTRIBUTIONS TO THREE COHESIVE RESE… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | DUARTE, CA-31 | 2024 | $3,298,435 |
ASST_NON_R01CA266665_075 ENGINEERED ANTI-PSCA ANTIBODIES FOR IMMUNOPET AND TARGETED THERAPY OF PANCREATIC CANCER - PANCREATIC CANCER REMAINS AMONG THE MOST LETHAL OF SOLID TUMORS, DUE TO LATE DIAGNOSIS AN… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | CA-90 | 2024 | $3,287,541 |
ASST_NON_R01DK102233_075 TARGETING AN ATYPICAL SIGNALING HUB TO RESTORE AND PROTECT WHOLE BODY GLUCOSE HOMEOSTASIS - PROJECT SUMMARY/ABSTRACT – TYPE 2 DIABETES (T2D) HAS NOW REACHED EPIDEMIC PROPORTIONS W… | Department of Health and Human Services National Institutes of Health | 93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | DUARTE, CA-31 | 2024 | $3,281,657 |
Top 50 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Federal Programs (CFDA)
View All→12345678910
93.395 — CANCER TREATMENT RESEARCH$121.9M
93.397 — CANCER CENTERS SUPPORT GRANTS$105.5M
93.847 — DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH$81.3M
93.393 — CANCER CAUSE AND PREVENTION RESEARCH$74.7M
93.396 — CANCER BIOLOGY RESEARCH$72.7M
93.837 — CARDIOVASCULAR DISEASES RESEARCH$46.0M
93.398 — CANCER RESEARCH MANPOWER$29.2M
93.394 — CANCER DETECTION AND DIAGNOSIS RESEARCH$26.3M
93.855 — ALLERGY AND INFECTIOUS DISEASES RESEARCH$18.5M
93.866 — AGING RESEARCH$18.5M
Source: USAspending.gov · All Recipients · New York